Navigation Links
Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
Date:3/11/2008

BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins(TM) technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal Taura virus. The specificity of the protective effect was established in control groups by chemically blocking the active regions in the vaccine, and as a result the protective effect was lost in these control groups. The effectiveness of this vaccine, and its rapid production cycle (7 days), represent an important proof of concept for developing vaccines against a range of rapidly replicating high lethality virus outbreaks.

For counteracting emerging infectious disease, early detection and rapid response are critical. Replikin contributions to date are both in early detection and rapid response: 1) Advance warning previously was not possible until it was found in H5N1 influenza that an increase in the virus replikin concentration signalled one year in advance that the outbreak was coming, and indicated the country in which this would occur (FluForecast(TM), Indonesia). 2) The production of vaccines by other methods has required 3 to 12 months, by which time the epidemic may have come and gone, or the vaccine effectiveness reduced or lost because the target changed due to mutation. In contrast, the replikins vaccine found effective here was manufactured synthetically in 7 days.

Viruses lethal to shrimp have been responsible for large losses to aquaculture worldwide. Replikins is forming a division to focus on these viruses. The company is also pursuing development of synthetic vaccine products based on replikin epitopes, Syntopes(TM), for the control of fish hemorrhagic viruses and other lethal aquatic microorganisms,

Contact: Replikins Ltd., 38 The Fenway, Boston MA 02215. email: sbogoch@replikins.com Tel: 646-320-5910

SOURCE Replikins Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
2. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
3. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
4. Combination vaccine protects monkeys from ebola and Marburg viruses
5. Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
6. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
7. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Vaccinex Antibody Licensed to GlaxoSmithKline
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... It is now ... (TBI) using single photon emission computed tomography (SPECT) according to researchers from ... which examined over 20,000 brain scans and is believed to be the largest brain ...
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... in reconstructive and aesthetic plastic surgeryMEDFORD, Mass., ... growth-stage medical device company developing silk-based biomaterial ... has received 510(k) clearance from the U.S. ... SeriScaffold (TM) silk-based, long term bioresorbable ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... the National Institute of Allergy and Infectious Diseases ... in Maryland, USA. The research collaboration involves formulating ... and exploring potential vaccines for HIV and malaria. ...
... its financial results for the year ending 31,December 2008. , , ... process for intravenous iclaprim in US, - Restructuring ... "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of CHF ...
Cached Biology Technology:Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... privacy of patients could be hampering efforts to spot ... pollution, according to researchers in the latest edition of ... made available to research groups investigating everything from cancer ... waste sites is often restricted, altered or aggregated in ...
... wild-type measles virus in tissues from patients who died ... notion that the strain of virus in the measles ... November 15 issue of The Journal of Infectious Diseases, ... could prevent many more cases of the disease, known ...
... uneasy at the sight of amassing gulls years ago, today ... an equally uneasy eye toward migratory birds, especially in Alaska, ... last week, in Siberia. , Alaska is at the intersection ... and scientists say that could provide an unusual mixing ground ...
Cached Biology News:Software 'agents' could help unmask reality of disease clusters 2New study shows measles immunization may prevent fatal brain infection 2On a wing and a prayer - Alaska researchers seek clues to bird flu 2On a wing and a prayer - Alaska researchers seek clues to bird flu 3
Griess Reagent component for determination of nitrite in aqueous solutions....
... Removal of excess dye terminators, template DNA, ... the true sequencing products have proved critical ... product is designed to work with dye ... and DYEnamicTM ET. The unique uniformity of ...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
... Freezing Point Osmometer for 10 L ... applications, including pediatric, neonatal, geriatric, general ... Automatic Calibration with 2 or 3 ... keypad and software for statistical analysis ...
Biology Products: